Sign up Australia
Proactive Investors - Run By Investors For Investors

Algae.Tec’s shares rise after licensing unique pharmaceutical delivery technology

Algae.Tec has signed a deal with a private Australian-based pharmaceutical delivery company.
a lab technician
Algae oil will be the base component

Algae.Tec Ltd’s (ASX:AEB) shares are trading circa 13% higher intra-day after licensing a patented mini emulsion-based delivery platform for pharmaceutical application.

The company has signed an agreement with a private Australian-based pharmaceutical delivery company, NS Technologies (NST) for the delivery platform technology.

Lower dosage with an effective outcome

The technology is one where a ‘mini-emulsion’ was developed to allow complex molecules to penetrate the epidermis skin layer, and enter the subdermal layer of the human body.

The mini-emulsion droplets filter through the epidermal layer, in an effective, “slow release” manner, allowing lower dosages, with an effective outcome.

This mini-emulsion base component requires a selected vegetable oil, which is ideally suited to specific algal oils.

Algae.Tec’s algal oils could be the base component

Under the agreement, Algae.Tec will acquire 19.9% of NST and exclusively license NST’s delivery platform technology for use across any medical application developed by Algae.Tec.

NST has also agreed to use AEB’s algae oil as the base component of its emulsion delivery platform.

The companies are aiming to develop a range of mini-emulsion pharmaceutical products for both human and veterinary purposes using selected algal oils.

READ: Algae.Tec to boost cash for medical cannabis cultivation plans

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AEB profile View Profile

Algae.Tec Timeline

Related Articles

oil and gas operations
May 01 2018
It was a year of portfolio building and progress for the onshore UK-focused minor, punctuated by improved production volumes and a number of acquisitions with value-adding potential
oil well
June 18 2018
A cash flow model - assuming one new IOsorb plant is added each year between 2019 and 2021 - gives a price target of 35p/share
oil and gas operations
July 09 2018
Greka highlighted improved revenues which boosted gross profit despite the challenges experienced in India and China through 2017.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use